Mechanistically, CPEB2 upregulates p21 expression by increasing its mRNA stability, thus further inducing cell cycle arrest. Taken together, our findings indicate that CPEB2 could be served as a new anticancer therapeutic target in glioma treatment. Here, CDKN1A is linked to glioma.